Humira Biosimilars Enter the Marketplace – Update on Navitus’ Review
The market entry of biosimilars to Humira® (adalimumab) is long-awaited. These products have the potential to improve affordability in the near- and...
Five Forecasts and Takeaways for Plan Sponsors in 2023
As we enter 2023, David Fields is sharing his top forecasts and takeaways for plan sponsors and the PBM industry.
Key Findings: 2021 Navitus Drug Trend Report
This week we provide an overview of our 2021 drug trend and client savings with insights for 2022 and beyond.
What You Need to Know About Fraud, Waste and Abuse in The Age of COVID-19
Carrie Aiken, Navitus’ Vice President of Corporate Compliance and Chief Compliance Officer, shares her perspective on how PBMs can help plan sponsors...
Using PMPM to Measure True Bottom Line Costs
Comparing one PBM to another is very complex. To add to it, many metrics are available to help you understand if you’re getting a good deal or not....
2022 Pharmacy Benefit Predictions: What Plan Sponsors Should Watch
Navitus’ CEO, David Fields, shares his insights into the pharmacy benefits industry that will help plan sponsors achieve greater cost savings,...
In the Pipeline: Specialty Drugs to Watch in 2022
Specialty medication development has grown rapidly, encompassing up to 80% of new FDA drug approvals in recent years. Read on to learn about the most...
In the Pipeline: Non-Specialty Drugs to Watch in 2022
Our pharmacists are always monitoring the drug development pipeline to help plan sponsors stay ahead of the curve on new and upcoming medications....
Using UM Strategies to Better Manage Rx Costs and Improve Health (rerun)
Utilization management (UM) programs serve as a gatekeeper to the formulary, working to ensure appropriate, cost-effective medication use. They can...
3 Key PBM Revenue Streams You Need to Know
Understanding how pharmacy benefit managers (PBMs) make money can help plan sponsors determine which PBM business model is best for their Rx plan –...
